Structural basis for the action of the drug trametinib at KSR-bound MEK
Structural basis for the action of the drug trametinib at KSR-bound MEK
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The MAPK/ERK kinase MEK is a shared effector of the frequent cancer drivers KRAS and BRAF that has long been pursued as a drug target in oncology
1
, and more recently in immunotherapy
2
,
3
and ageing
4
. However, many MEK inhibitors are limited owing to on-target toxicities
5
–
7
and drug resistance
8
–
Alternative Titles
Full title
Structural basis for the action of the drug trametinib at KSR-bound MEK
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7746607
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7746607
Other Identifiers
ISSN
0028-0836
E-ISSN
1476-4687
DOI
10.1038/s41586-020-2760-4
